Together, we accelerate
China market access
We partner with innovators to bring high-impact therapies to patients across China and key global markets—measured in months, not years.
LEARN MORE →End-to-End China Market Access
Our China business is headquartered in the Macau SAR, with offices in Hong Kong and Mainland China and a nationwide sales team covering every province. We are a full-suite pharmaceutical company dedicated to introducing innovative global therapies to China, supported by end-to-end registration to distribution capabilities.
Key facts
- Established in-country since 2017
- 800+ Greater China staff
- 7 Greater China subsidiaries
- 100 + full product approvals
- 7 + approvals in pipeline
- 300+ partner companies
Fast-Track Execution. Nationwide Reach.
Working with our local affiliates, we have registered 100+ products in China via the Macau Fast-Track pathway over the past five years, expanding access to important therapies for patients across the region. Building on deep regulatory relationships, strong execution, and a repeatable dossier-and-launch playbook, our Macau and Hong Kong–based commercial teams and nationwide coverage are scaling our portfolio across multiple modalities—including advanced therapies such as cell therapy—to bring more high-quality, innovative treatments to China and beyond.
Product Introduction & Distribution
We help pharmaceutical companies enter China quickly through end-to-end registration and commercialization, using an asset-light model where we cover local execution costs.
Drug Registration & Approval
We register medicines and medical devices through Macau and Hong Kong, enabling accelerated access to Mainland China via pilot pathways in the Greater Bay Area and Hainan—supported by relationships with major hospitals nationwide.
Cross-Border Distribution
We pair cross-border distribution (e.g., Tmall Global, JD Worldwide/JD International) with hospital access, powered by a KOL-led, top-down strategy—supported by a merchant network reaching ~70% of leading players.